ALB and neoplasm: In addition, exploiting the binding to endogenous human serum albumin (HSA) is a valuable option to achieve tumor targeting and improve the pharmacokinetic profile of drugs and nanosystems (Zhang et al., 2018; Chen et al., 2022; Li et al., 2022).